NYSE: HCAHca Healthcare Inc Stock
$345.08+4.50 (+1.32%)
Updated Apr 30, 2025
HCA Price
$345.08
Fair Value Price
N/A
Market Cap
$85.70B
52 Week Low
$289.98
52 Week High
$417.14
P/E
15.5x
P/B
-34.29x
P/S
1.1x
PEG
1.21x
Dividend Yield
0.78%
Revenue
$70.60B
Earnings
$5.76B
Gross Margin
40.6%
Operating Margin
13.72%
Profit Margin
8.2%
Debt to Equity
-23.59
Operating Cash Flow
$11B
Beta
0.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HCA Overview
HCA Healthcare, Inc. operates for-profit health care facilities. The company owns and operates 186 hospitals and 2,000 other sites of care (surgery centers, freestanding emergency rooms, urgent care centers, and physician clinics) in the U.S and UK. HCA Healthcare was founded in 1968 and is based in Nashville, TN.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HCA's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
HCA
Ranked#13 of 42
Ranked#13 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.88 | A | |
| $12.73 | A | |
| $14.21 | A |
Be the first to know about important HCA news, forecast changes, insider trades & much more!
HCA News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HCA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HCA ($345.08) is trading above its intrinsic value of $228.06, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HCA is good value based on its earnings relative to its share price (15.5x), compared to the US market average (29.18x)
P/E vs Market Valuation
HCA is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more HCA due diligence checks available for Premium users.
Valuation
HCA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
15.5x
Industry
14.9x
Market
29.18x
HCA is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HCA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
HCA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-34.29x
Industry
4.38x
HCA price to earnings growth (PEG)
For valuing profitable companies with growth potential
HCA is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
HCA's financial health
Profit margin
Revenue
$18.3B
Net Income
$1.4B
Profit Margin
7.9%
HCA's Earnings (EBIT) of $9.69B... subscribe to Premium to read more.
Interest Coverage Financials
HCA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$59.5B
Liabilities
$59.0B
Debt to equity
-23.59
HCA's short-term assets ($16.41B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HCA's long-term liabilities ($43.78B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HCA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HCA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.6B
Investing
-$1.3B
Financing
-$2.2B
HCA's operating cash flow ($10.51B)... subscribe to Premium to read more.
Debt Coverage Financials
HCA vs Medical Care Facility Stocks
Hca Healthcare Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.